



26 M.B.B.S., FCPS  
27 Associate Professor  
28 Departments of Surgery  
29 Aga Khan University, Karachi, Pakistan  
30 Contact e-mail: [riaz.lakdawala@aku.edu](mailto:riaz.lakdawala@aku.edu)  
31 Contact Number: +92-21-34864753  
32 **Dr. Masood Umer**  
33 M.B.B.S., FCPS  
34 Professor & Section Head  
35 Departments of Surgery  
36 Aga Khan University, Karachi, Pakistan  
37 Contact e-mail: [masood.umer@aku.edu](mailto:masood.umer@aku.edu)  
38 Contact Number: +92-21-34864736  
39 **Corresponding Author:**  
40 **Dr. Zehra Abdul Muhammad**  
41 M.B.B.S., M.S.  
42 Senior Instructor (Research)  
43 Department of Surgery  
44 The Aga Khan University  
45 Stadium Road, P.O. Box 3500  
46 Karachi 74800, Pakistan  
47 Contact e-mail: [zehra.abdul@aku.edu](mailto:zehra.abdul@aku.edu)  
48 Contact Number: +92-21-34864746, +92 3212198901  
49

50 **Author contributions:** Dr. Tashfeen Ahmad and Dr. Zehra Abdul Muhammad contributed to the study  
51 Data interpretation and critical manuscript review, Dr. Zehra Abdul Muhammad contributed to the study  
52 design, concept, questionnaire design, Literature search, data collection with analysis, manuscript writing,  
53 data interpretation, Dr. Yasir Mohib, Dr. Riaz Hussain, and Dr. Masood Umer provided feedback with a  
54 critical manuscript review.  
55

56

## Abstract

57 **Background:** Over or sub-optimal analgesic treatment leads to undesired consequences and  
58 patient dissatisfaction. The study aims to assess the sub-optimal or optimal pain relief and safety  
59 of routinely prescribed oral analgesic(s) at discharge and 1-week post-discharge in ankle and foot  
60 fracture surgeries.

61 **Methods:** The ongoing prospective cohort study data on 54 ankle and hindfoot trauma fracture  
62 adult patients enrolled between June 2022 to July 2023 was analyzed. Post-surgery oral analgesics  
63 prescribed at hospital discharge and 1-week follow-up were stratified for assessing adverse events  
64 and pain (Visual Analogue Scale) at 1- and 2 weeks post-discharge. The relationship of age,  
65 gender, and comorbidity was analyzed by multiple logistic regression for adverse events and  
66 multiple linear regression for pain score.

67 **Results:** Median pain scores at 1- and 2-week follow-ups were 3.2 (IQR=3.0) and 2 (IQR=2.0)  
68 respectively. Combinations of tramadol, acetaminophen with naproxen or diclofenac or  
69 orphenadrine; and naproxen, pregabalin, with acetaminophen seemed toxic with sub-optimal pain  
70 control. Similar results were for celecoxib combined with pregabalin and etoricoxib combined  
71 with diclofenac or tramadol. Acetaminophen alone was safe but occasionally showed intolerance.  
72 Etoricoxib or diclofenac alone or with acetaminophen was safe and showed better pain control in  
73 this cohort. A regression model was non-significant for a relationship between covariates and pain  
74 scores or adverse events.

75 **Conclusion:** Current data suggests that certain oral analgesics or their combinations are harmful  
76 with sub-optimal pain control while some are safe and effective. Choosing suitable analgesics or  
77 their combinations in specific fractures might reduce patient harm with optimal pain management.

78 **Keywords:** Ankle fracture, Hindfoot fracture, Trauma, Optimal pain management, Adverse  
79 events, Oral analgesics.

80

81 **Introduction:**

82 The ankle and hindfoot are essential anatomical parts for controlling body balance, and mobility.  
83 If fractured, there is difficulty in ambulation and fracture pain further restricts these movements.  
84 Fracture pre-and post-treatment pain control is essential to reduce patient distress, but over or sub-  
85 optimal treatment leads to undesired consequences and results in readmissions, prolonged  
86 treatment, and patient dissatisfaction. Further to this, while selecting analgesics, pain control is  
87 mainly focused, ignoring potential patient harm. Parenteral analgesics are usually switched to oral  
88 analgesics at the time of hospital discharge to control pain for ambulation and rehabilitation. To  
89 optimize pain management, it is of utmost importance to choose analgesics that timely and  
90 adequately manage pain and have negligible side effects.

91 There is scarce data available on optimal pain management (including pain relief as well as  
92 analgesic safety) for specific fractures in adults [1-6]. Some pain management standards like The  
93 National Institute for Health and Care Excellence (NICE) guideline, Centers for Disease Control  
94 and Prevention (CDC), and some research studies recommend acetaminophen as the first treatment  
95 choice followed by either NSAIDs or opioids depending on fracture type, site, etc. [7, 8]. In the  
96 NICE guide, pain management for ankle and foot fractures is also specified. Oral acetaminophen  
97 is recommended as an initial treatment for ankle fractures. Codeine could be added for  
98 uncontrolled pain with further addition of NSAIDs as required but with due care in elderly and  
99 frail adults [7]. Injectable morphine might be administered in uncontrolled ankle fracture pain with  
100 special attention in elderly and frail adults [7, 9]. Furthermore, certain research studies developed  
101 ankle and foot fracture pain management protocols with a reduced number of analgesic quantities  
102 while in some studies patient satisfaction with better ankle fracture pain control was assessed [10-

103 12]. Some randomized controlled trials were performed to assess safety and pain control by certain  
104 analgesics in ankle and foot fracture surgeries [13, 14].

105 It is essential that practitioners have sound knowledge about appropriate analgesic selection that  
106 controls pain effectively and is safe. The study aims to assess the extent of pain relief and safety  
107 of oral analgesic(s) routinely prescribed in ankle and foot fracture surgeries at discharge and 1-  
108 week post-discharge at a tertiary care hospital. This will allow us to identify the analgesics or their  
109 combinations that either adequately control pain with better tolerance or inadequately control pain  
110 with potential toxicity. The current evidence will help maximize benefit and reduce patient harm  
111 by selecting appropriate and safe analgesics for ankle and hind foot trauma fracture pain  
112 management and thus, optimize orthopaedic surgeons analgesic prescribing practice.

113

#### 114 **Methods:**

115 After obtaining Ethical Review Committees and Institutional approvals, the observational,  
116 prospective cohort study was initiated in June 2022. The adult patient population with ankle or  
117 hindfoot trauma fractures of any gender who arrived at a tertiary care hospital between June 2022  
118 to July 2023 and were surgically managed were included. Those patients who were unable to  
119 consent or had undergone limb amputation were excluded. The patient's written informed consent  
120 was obtained as per Good Clinical Practice guidelines before study enrollment. The demographics  
121 and prescribed oral analgesics at patient discharge and 1-week follow-up were recorded.  
122 Continuous variables like for age, normality of distribution was assessed for normality of  
123 distribution using the Shapiro Wilk test. For qualitative variables, frequency and percentages were  
124 used. Patients were followed at 1- and 2-week post-discharge to assess their pain control using a  
125 visual analogue scale (0=no pain, 1-3=mild, 4-6=moderate, and 7-10=severe pain scores) as well

126 as any adverse events (reported by patients or were clinically examined/identified) likely with  
127 prescribed oral analgesics at discharge and 1-week follow-up respectively. Oral analgesics or their  
128 combinations prescribed at discharge and 1-week follow-up were stratified. Analgesics with sub-  
129 optimal pain control and toxicity or with optimal pain control and tolerance were isolated. The  
130 relationship of covariates age gender, and comorbid condition was evaluated between adverse  
131 events or pain scores assessed at 1- and 2-week follow-ups using multiple logistic regression or  
132 multiple linear regression analysis respectively. The  $p$ -value  $<0.05$  was considered statistically  
133 significant with a confidence interval of 95%.

134

### 135 **Results:**

136 During almost one year time, 54 ankle and hindfoot fracture patients were enrolled in the study in  
137 which ankle fractures 46 (85%), hindfoot 7 (13%), and both ankle and hindfoot fractures 01 (2%).  
138 Males were 33 (61%) while females were 21 (39%). The median age was 46 (IQR=25). The most  
139 common mechanisms of injury were falls (N=24, 44%) and road traffic accidents (N=23, 43%).  
140 Median pain scores were 3.2 (IQR=3.0) and 2.0 (IQR=2.0) at 1- and 2-week follow-ups  
141 respectively.

142 At 1 week follow-up, 25 (46%) patients were free of any AE/SAE while 29(54%) experienced  
143 either AE (N=17) or SAE (N=12) potentially due to analgesics prescribed at the time of discharge.

144 At 2 weeks follow-up, 38(70%) patients were free of AE/SAE while 16(30%) experienced either  
145 AE (N=12) or SAE (N=04) potentially due to 1-week prescribed analgesics. No mortality was  
146 reported at both follow-ups.

147 On stratification (Figures 1 and 2), the prescribed analgesics showing toxicity and with sub-  
148 optimal pain control or analgesics showing better pain control and tolerance at 1- and 2-week



149 follow-ups were segregated. It was observed that analgesic combinations like the combination of  
150 acetaminophen, tramadol, and diclofenac (N=8) showed several SAEs (N=3) and AE (N=2) with  
151 moderate pain in half of the patients at follow-ups. Naproxen, acetaminophen, and pregabalin with  
152 or without adding thiocolchicoside or tizanidine (N=3) showed SAE (N=1) or AE (N=1) with  
153 mostly moderate pain. Adding tramadol in the analgesic combination naproxen, acetaminophen,  
154 and pregabalin (N=2) shows AE (N=1) and mild/moderate pain. Combining naproxen,  
155 acetaminophen, and tramadol (N=2) also showed AE in both patients with mild/severe pain.

156

157 **Figure 1:** Discharge analgesics with potential SAE/AEs (A) and pain control (B).

158

159 **Figure 2:** Analgesics prescribed at 1-week follow-up with potential SAE/AEs (A) and pain control  
160 (B).

161

162 Patients treated with the combination of acetaminophen and orphenadrine with or without adding  
163 tramadol (N=5) experienced SAE (N=3) and AE (N=1) with inadequate pain control in the  
164 majority at follow-ups. Combination of celecoxib, and acetaminophen (N=4) showed AE (N=2)  
165 and no to moderate pain. If celecoxib was combined with pregabalin or tramadol (N=3) showed  
166 AE (N=2) with severe pain (N=2). Meloxicam when administered alone (N=4) showed SAE (N=1)  
167 and AE (N=2) with none to moderate pain. When meloxicam was combined with tramadol and  
168 acetaminophen (N=2) showed no AE with mild/moderate pain (N=2).

169 Tramadol, when combined with acetaminophen (N=9) produced AEs (N=4) but pain was well  
170 controlled in these patients at follow-ups.

171 Some analgesics in certain analgesic combinations worked well while when combined with some  
172 other analgesics showed toxicity and inadequate pain control. Analgesic etoricoxib (N=2) had no  
173 AE/SAE and no/mild pain. Adding acetaminophen in etoricoxib (N=1) showed no AE/SAE but  
174 moderate pain. If etoricoxib was combined with tramadol or diclofenac (N=3) showed SAE (N=1)  
175 or AE (N=1) with no to moderate pain. Patients treated with diclofenac with or without  
176 acetaminophen (N=7) experienced only mild AE (N=2) with no/mild pain in the majority.  
177 Acetaminophen (N=6) administration showed SAE (N=1) with no to moderate pain. The  
178 combination of pregabalin and acetaminophen (N=5) with or without tramadol showed no  
179 SAE/AE and pain was none or mild in the majority.  
180 On applying multiple logistic regression, the model was non-significant for AEs assessed at 1-  
181 ( $X^2(3) = 0.47, p=0.9$ ) and 2 weeks ( $X^2(3) = 3.9, p=0.26$ ) to covariates age ( $p=0.9, 0.6$ ), gender  
182 ( $p=0.7, 0.6$ ), and comorbidity binary variable ( $p=0.6, 0.2$ ) with Nagelkerke  $R^2=0.01$  and  $0.1$ ,  
183 respectively. The multiple linear regression model was non-significant for pain score at 1- and 2-  
184 week follow-ups and covariates age ( $p=0.1, CI= -0.67-0.13; p=0.9, CI= -0.03-0.03$ ), gender ( $p=0.7$ ,  
185  $CI= -1.2-0.9; p=0.1, CI= -1.6-0.2$ ), and comorbidity binary variable ( $p=0.1, CI= -0.2-2.3; p=0.2$ ,  
186  $CI= -0.4-1.8$ ) with  $R^2=0.05$  and  $0.07$  respectively.

187

## 188 **Discussion:**

189 In the current data, it was observed that some oral analgesics prescribed to ankle or hindfoot  
190 fracture patients at discharge or at 1-week follow-up are sub-optimal in controlling pain and  
191 showed toxicity at 1- and/or 2-week follow-ups respectively. When acetaminophen, tramadol, and  
192 diclofenac were combined, several central nervous system (CNS) and cardiovascular side effects  
193 were reported like anxiety, insomnia, headache, dizziness, angina, hypotension, hypertension, etc.

194 with sub-optimal pain control. In the literature, diclofenac risks are reported, particularly  
195 cardiovascular events [15, 16]. Additionally, some evidence shows that combining tramadol and  
196 diclofenac can cause CNS and GIT side effects but contrary to our findings, better analgesia was  
197 observed in these studies [17-19].

198 Another combination of naproxen, acetaminophen pregabalin with or without adding other  
199 analgesics like thiocolchicoside or tizanidine or tramadol showed sub-optimal pain control with  
200 GIT, cardiovascular (CVS), and CNS toxicity like hypotension, headache, anorexia, dysphagia,  
201 constipation, oral ulcers, diarrhea, weakness, cough etc. Similar reports are available on tramadol  
202 and naproxen toxicity and sub-optimal pain control on opioid use [20-27]. In addition to the above  
203 analgesic combinations, acetaminophen and orphenadrine including or not tramadol showed sub-  
204 optimal pain control with toxicity like hypotension, hypertension, dyspnea, sweating, dysuria,  
205 anorexia, depression, etc. There is scarce literature available on the toxicity of this combination  
206 [28].

207 When celecoxib and acetaminophen were combined showed better pain control in the majority and  
208 produced gastrointestinal (GIT) side effects like constipation, nausea, and vomiting. The addition  
209 of pregabalin in this combination produced CNS and GIT side effects like insomnia, constipation,  
210 diarrhea, etc. with sub-optimal pain control. Our finding is contrary to available scarce evidence  
211 of celecoxib with pregabalin being safe and effective in spinal surgery [29]. As the indication of  
212 pain management is different, the results may vary. Celecoxib toxicity is also reported for CNS,  
213 GIT, and CVS systems [30, 31].

214 Meloxicam when taken alone, one 30-year-old patient experienced SAE hypotension with no  
215 underlying comorbidity. Besides this, GIT-related side effects were also observed in patients like

216 constipation and diarrhea. The pain was mostly well controlled. The side effects of meloxicam are  
217 commonly related to GIT problems, but cerebrovascular side effects are also known [32-34].  
218 Etoricoxib when combined with acetaminophen was safe with no side effects and better pain  
219 control in ankle and hind foot fractures but when tramadol or diclofenac is added, the combination  
220 showed severe CNS toxicity like memory loss, blurred vision, fatigue, dry mouth along with GIT  
221 problems like anorexia, constipation, nausea with sub-optimal pain control. Few reports are  
222 available for this combination in which side effects of etoricoxib when combined with diclofenac  
223 are mentioned like GIT and CNS problems including seizures, hypertension, etc. [35-38]  
224 Analgesic pregabalin alone or with acetaminophen and tramadol showed no AE with none to  
225 moderate pain. Rare reports are available for this combination which showed better pain control  
226 with AEs like somnolence, dizziness, and blurred vision [39].  
227 In the literature, acetaminophen is reported to be a safe analgesic [40, 41]. In the present research,  
228 mostly there was no harm observed after acetaminophen administration except for one 24-year-  
229 old pregnant lady with no underlying comorbidity who experienced hypotension. It was also  
230 observed that pain control was sub-optimal with acetaminophen alone. The literature reports  
231 similar systemic events including hypotension after taking acetaminophen [42-48].  
232 In our ankle and hindfoot fracture population, analgesic diclofenac with or without acetaminophen  
233 optimally controlled pain as well as was safe in ankle and hindfoot fractures. When diclofenac was  
234 combined with tramadol showed SAE/AEs but when prescribed alone or in combination with  
235 acetaminophen, it seemed safe and had better pain control.

236

237 **Conclusion:**

238 Thus, in the current ankle and hindfoot fractures data on oral analgesics management, it was  
239 observed that certain analgesic combinations were sub-optimal in controlling pain and were toxic  
240 like combinations of tramadol with diclofenac/naproxen; naproxen, pregabalin and  
241 acetaminophen; etoricoxib with tramadol/diclofenac; orphenadrine with acetaminophen with or  
242 without tramadol; and celecoxib with acetaminophen with or without tramadol/pregabalin.  
243 Changing some sets of analgesic combinations were safe and had better pain control like etoricoxib  
244 or diclofenac with or without combining with acetaminophen showed better tolerance and pain  
245 control in ankle and hindfoot fracture patients. The current stratification of harmful and safe  
246 analgesic combinations might assist in optimal pain management of specific fractures by selecting  
247 safe analgesics that have better pain control.

248

249 **Limitation:**

250 This is a single-center study and thus, the generalizability of findings was not achieved. The  
251 analgesics to AE relationship was not determined thoroughly by root cause analysis.

252

253 **Disclosure:**

254 The authors report no proprietary or commercial interest in any product mentioned or concept  
255 discussed in this article.

256

257 **Funding:**

258 The study was generously supported by the Orthopaedic Trauma Association (proposal ID #6704,  
259 <https://ota.org/>). The award was received by TA, ZM, and YM.

260

261 **Conflict of interest:**

262 The Authors declare that there are no conflicts of interest regarding the publication of this article.

263

264 **Data availability:**

265 On reasonable request, data will be provided.

266

267 **References:**

268 1. Drendel AL, Gorelick MH, Weisman SJ, Lyon R, Brousseau DC, Kim MK. A randomized  
269 clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture  
270 pain. *Ann Emerg Med.* 2009;54(4): 553-560.

271 2. Charney RL, Yan Y, Schootman M, Kennedy RM, Luhmann JD. Oxycodone versus codeine  
272 for triage pain in children with suspected forearm fracture: a randomized controlled trial.  
273 *Pediatr Emerg Care.* 2008;24(9): 595-600.

274 3. Friday JH, Kanegaye JT, McCaslin I, Zheng A, Harley JR. Ibuprofen provides analgesia  
275 equivalent to acetaminophen-codeine in the treatment of acute pain in children with extremity  
276 injuries: a randomized clinical trial. *Acad Emerg Med.* 2009;16(8): 711-716.

277 4. Clark E, Plint AC, Correll R, Gaboury I, Passi B. A randomized, controlled trial of  
278 acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal  
279 trauma. *Pediatrics.* 2007;119(3): 460-467.

280 5. Benhamed A, Boucher V, Emond M. Pain management in emergency department older adults  
281 with pelvic fracture: still insufficient. *Canadian Journal of Emergency Medicine.* 2022;24(3):  
282 245-246.

- 283 6. Apostolopoulos A, Kiriakidis A, Xrisanthopoulou M, Anastasopoulos P, Antoniou D, Liakou  
284 K, et al. Parecoxib as a post surgical analgesic drug in fractures of the hip joint in comparison  
285 with diclofenac-pethidine. *Orthop Procs.* 2006;88–B Suppl 1:186
- 286 7. NICE. Fractures (non-complex): assessment and management; 2016 [cited 2022 October 12].  
287 Available from:  
288 [https://www.nice.org.uk/guidance/NG38/chapter/Recommendations#ongoing-orthopaedic-](https://www.nice.org.uk/guidance/NG38/chapter/Recommendations#ongoing-orthopaedic-management)  
289 management.
- 290 8. Centers for Disease Control and Prevention (CDC) guidelines for prescribing opioids for pain  
291 - United States; 2022 2023 [updated January 31, 2023; cited 2023 March 27]. Available from:  
292 <https://www.guidelinecentral.com/guideline/2214777/>.
- 293 9. NICE. Complex fractures; 2016 [cited 2023 April 06]. Available from:  
294 [https://www.nice.org.uk/guidance/ng37/resources/fractures-complex-assessment-and-](https://www.nice.org.uk/guidance/ng37/resources/fractures-complex-assessment-and-management-pdf-1837397402053)  
295 management-pdf-1837397402053.
- 296 10. Troy Boffeli D, Catlea Gorman D. A guide to postoperative pain management. *Podiatry*  
297 *Today.* 2018;31(9).
- 298 11. Xu AL, Humbyrd CJ. Strategies for Reducing Perioperative Opioid Use in Foot and Ankle  
299 Surgery: Education, Risk Identification, and Multimodal Analgesia. *Orthopedic Clinics.* 2023.
- 300 12. Helmerhorst GTT, Lindenhovius ALC, Vrahas M, Ring D, Kloen P. Satisfaction with pain  
301 relief after operative treatment of an ankle fracture. *Injury.* 2012;43(11): 1958-1961.
- 302 13. Jarde O, Boccard E. Parenteral versus Oral Route Increases Paracetamol Efficacy. *Clin Drug*  
303 *Investig.* 1997;14(6): 474-481.
- 304 14. Soulier SM, Page JC, Larsen LC, Grose BC. The efficacy of ANSAID (flurbiprofen) as an  
305 analgesic in foot surgery. *J Foot Ankle Surg.* 1997;36(6): 414-417.

- 306 15. Whelton A, Lefkowitz JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as  
307 compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. *Kidney*  
308 *Int.* 2006;70(8): 1495-502.
- 309 16. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of  
310 nationwide cohort studies. *BMJ.* 2018;362: k3426.
- 311 17. Mitra S, Khandelwal P, Sehgal A. Diclofenac-tramadol vs. diclofenac-acetaminophen  
312 combinations for pain relief after caesarean section. *Acta Anaesthesiol Scand.* 2012;56(6):  
313 706-711.
- 314 18. Shareef SM, Sridhar I, Dakshayani KM, Rao YV, Santhamma B. Evaluation of the effects of  
315 tramadol and diclofenac alone and in combination on post-cesarean pain. *Int J Basic Clin*  
316 *Pharmacol [Internet].* 2017;3(3): 470-473.
- 317 19. Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitization and pain  
318 after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and  
319 in combination. *Anesth Analg.* 2003;97(2): 526-533.
- 320 20. Cossmann M, Kohlen C, Langford R, McCartney C. [Tolerance and safety of tramadol use.  
321 Results of international studies and data from drug surveillance]. *Drugs.* 1997;53 Suppl 2: 50-  
322 62.
- 323 21. Hallberg P, Brenning G. Angioedema induced by tramadol—a potentially life-threatening  
324 condition. *Eur J Clin Pharmacol.* 2005;60(12): 901-903.
- 325 22. Dhingra H. Naproxen; 2022 [cited 2023 March 27]. Available from:  
326 <https://www.buzzrx.com/naproxen-coupon/side-effects>.
- 327 23. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of Opioid  
328 vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or



- 329 Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. *JAMA*.  
330 2018;319(9): 872-882.
- 331 24. Sutton LB. Naproxen sodium. *J Am Pharm Assoc (Wash)*. 1996;Ns36(11):663-7.
- 332 25. Al-Abri SA, Anderson IB, Pedram F, Colby JM, Olson KR. Massive naproxen overdose with  
333 serial serum levels. *J Med Toxicol*. 2015;11(1): 102-105.
- 334 26. Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic  
335 pain. *Neuropsychiatr Dis Treat*. 2007;3(6): 885-891.
- 336 27. Ho JM, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, et al. Pregabalin and  
337 heart failure: A population-based study. *Pharmacoepidemiol Drug Saf*. 2017;26(9): 1087-  
338 1092.
- 339 28. Park YS, Kim YB, Kim JM. Status epilepticus caused by nefopam. *J Korean Neurosurg Soc*.  
340 2014;56(5): 448-450.
- 341 29. Zhang Y, He B, Zhao J, Zhang M, Ren Q, Zhang W, et al. Addition of Celebrex and Pregabalin  
342 to Ropivacaine for Posterior Spinal Surgery: A Randomized, Double-Blinded, Placebo-  
343 Controlled Trial. *Drug Des Devel Ther*. 2021;15: 735-742.
- 344 30. Barcella C, Lamberts M, McGettigan P, Fosbøl E, Lindhardsen J, Torp-Pedersen C, et al.  
345 Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A  
346 nationwide study in patients with osteoarthritis. *Basic Clin Pharmacol Toxicol*. 2018;124.
- 347 31. Searle. Product Information. Celebrex (celecoxib); 2001 [cited 2023 October 18]. Available  
348 from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2001/20998s10lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20998s10lbl.pdf).
- 349 32. Khalil NY, Aldosari KF. Meloxicam. *Profiles Drug Subst Excip Relat Methodol*. 2020;45:  
350 159-197.

- 351 33. Poverennova IE, Zolotovskaya IA. [Cerebrovascular risks and prediction of complications in  
352 patients with backache during therapy with nonsteroidal anti-inflammatory drugs]. *Ter Arkh.*  
353 2015;87(5): 53-57.
- 354 34. Dalal D, Dubreuil M, Peloquin C, Neogi T, Zhang Y, Choi H, et al. Meloxicam and risk of  
355 myocardial infarction: a population-based nested case-control study. *Rheumatol Int.*  
356 2017;37(12): 2071-2078.
- 357 35. Arnao V, Riolo M, Fierro B, Aridon P. Seizure following the Use of the COX-2 Inhibitor  
358 Etoricoxib. *Case Rep Neurol Med.* 2017;2017: 1410759.
- 359 36. Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, et al. Gastrointestinal  
360 side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus  
361 Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. *J*  
362 *Rheumatol.* 2007;34(2): 408-420.
- 363 37. Drugbank. Etoricoxib; 2021 [cited 2023 December 01]. [Entry 366]. Available from:  
364 <https://go.drugbank.com/drugs/DB01628>.
- 365 38. Thumtecho S, Wainipitapong S, Tantakitti P. Transient depersonalisation/derealisation  
366 syndrome from tramadol. *BMJ Case Rep.* 2023;16(6): e254909.
- 367 39. Hassab ARM, Fawzy HM, Elfawal SM, Kamaleldin DM. Comparative study between  
368 paracetamol versus paracetamol and pregabalin combination for postoperative analgesia in  
369 hip surgeries. *QJM: Int J Med.* 2020;113(Supplement\_1).
- 370 40. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or  
371 their combination in postoperative pain management: a qualitative review. *Br J Anaesth.*  
372 2002;88(2): 199-214.

- 373 41. Verkleij SP, Luijsterburg PA, Bohnen AM, Koes BW, Bierma-Zeinstra SM. NSAIDs vs  
374 acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity  
375 influencing the outcomes. *Osteoarthr Cartil.* 2011;19(8): 921-929.
- 376 42. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal  
377 antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. *Circulation.*  
378 2006;113(12): 1578-1587.
- 379 43. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic  
380 analgesic use and decline in renal function in women. *Arch Intern Med.* 2004;164(14): 1519-  
381 1524.
- 382 44. Pezzia C, Sanders C, Welch S, Bowling A, Lee WM. Psychosocial and behavioral factors in  
383 acetaminophen-related acute liver failure and liver injury. *J Psychosom Res.* 2017;101: 51-  
384 57.
- 385 45. Lee BT, Odin JA, Grewal P. An Approach to Drug-Induced Liver Injury from the Geriatric  
386 Perspective. *Curr Gastroenterol Rep.* 2021;23(4): 6.
- 387 46. Zyoud SH, Awang R, Sulaiman SA, Al-Jabi SW. Association between gastrointestinal  
388 manifestations following acetaminophen poisoning and outcome in 291 acetaminophen  
389 poisoning patients. *Pharmacoepidemiol Drug Saf.* 2010;19(5): 511-517.
- 390 47. Brown G. Acetaminophen-induced hypotension. *Heart Lung.* 1996;25(2): 137-140.
- 391 48. Danguy des Déserts M, Nguyen BV, Giacardi C, Commandeur D, Paleiron N.  
392 [Acetaminophen-induced hypotension after intravenous and oral administration]. *Ann Fr*  
393 *Anesth Reanim.* 2010;29(4): 313-314.




Figure 1

Figure 1




Figure 2

Follow-up 1-week prescribed oral analgesics

Figure 2